Moreover, in estrogen receptor-positive BC cells, ATG inhibits tumor proliferation by facilitating GSK3-mediated degradation of cyclin D1 and inducing cell cycle arrest, indicating its promise as a multi-targeted therapeutic treatment for BC (Zhu et al., 2020). Here, ESR1 is linked to breast cancer.